Aquestive Therapeutics (AQST)
NASDAQ:AQST
Want to see AQST full AI Analyst Report?
AQST Stock Chart & Stats
$4.24
-$0.11(-3.57%)
At close: 4:00 PM EST
$4.24
-$0.11(-3.57%)
Day’s Range― - ―
52-Week Range$2.12 - $7.55
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.70M
Market Cap
$517.47M
Enterprise Value$431.34M
Total Cash (Recent Filing)$121.17M
Total Debt (Recent Filing)$131.44M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
May 05, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding122,045,050
10 Day Avg. Volume910,394
30 Day Avg. Volume1,698,020
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-23.41
Price to Sales (P/S)17.69
P/FCF Ratio-14.87
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue9.68
Enterprise Value/Gross Profit16.60
Enterprise Value/Ebitda-6.67
Forecast
1Y Price Target
$8.86Price Target Upside108.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$49.35M
Bulls Say, Bears Say
Bulls Say
Commercial CompetitivenessAnalyst notes the sublingual treatment shows pharmacokinetics comparable to injectables while offering easier use and greater portability, supporting strong patient preference and potential uptake versus autoinjectors.
Regulatory ValidationFDA feedback raised no concerns about the product's safety, efficacy, pharmacokinetics, repeat-dose safety, durability, or manufacturing, with deficiencies confined to packaging and user handling, suggesting the core clinical package remains intact.
Remediation Plan And LeadershipManagement redesigned the pouch and labeling, plans to run human factors and pharmacokinetic studies in parallel, and added an experienced allergy specialist as chief medical officer, indicating a clear and experienced path toward resubmission.
Bears Say
Financial Performance And Cash RunwayRecent quarterly results missed expectations with lower revenue and wider losses, and continued adjusted EBITDA deficits plus declining cash reserves could constrain financial flexibility until commercial revenues scale.
Human Factors And Approval Delay RiskThe FDA's Complete Response Letter cited difficulty opening the pouch and incorrect film placement as safety risks, and unresolved packaging and user-handling requirements could delay approval or resubmission.
Market Competition RiskAnalyst warns that a delayed U.S. launch due to packaging or testing setbacks may allow competitors to gain market share, undermining the product's commercial opportunity.
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.12 and its highest was $7.55 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $517.47M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is May 05, 2026 which is in 18 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Mar 04, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.13.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 122,045,050 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.517%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aquestive Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.86 (108.89% Upside)
$8.86 (108.89% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
64.68%
12-Months-Change
Fundamentals
Return on Equity
195.65%
Trailing 12-Months
Asset Growth
59.89%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveys a cautiously optimistic operational and regulatory outlook: management has clarified a concrete plan and timeline to address the FDA's CRL, strengthened the clinical and commercial teams, secured additional investor support and maintains a healthy cash balance entering 2026. However, financial performance shows materially wider losses and negative adjusted EBITDA versus prior year, driven by increased SG&A (notably legal and prelaunch commercial spending), and approval still depends on completing and executing additional studies that create timing and execution risk. Competitive pressures and meaningful near-term cash burn temper the enthusiasm.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$8.86
▲(108.89% Upside)
Technical Analysis
Emergent Biosolutions
―
SIGA Technologies
―
Esperion
―
Organogenesis Holdings
―
Evolus
―
Ownership Overview
2.94% Insiders
8.86% Mutual Funds
0.22% Other Institutional Investors
79.58% Public Companies and
Individual Investors